Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending September 30, 2023 was $-22 Million (a -47.22% decrease compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss increased by 12.96%
- Annual Consolidated Net Income/Loss for 2022 was $-105 Million (a 3.91% increase from previous year)
- Annual Consolidated Net Income/Loss for 2021 was $-101 Million (a 603.41% increase from previous year)
- Annual Consolidated Net Income/Loss for 2020 was $-14.4 Million (a 118.0% increase from previous year)
- Twelve month Consolidated Net Income/Loss ending September 30, 2023 was $-106 Million (a -4.71% decrease compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss increased by 1.51% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| $-106 Million | $-112 Million | $-98.8 Million | $-105 Million |
Visit stockrow.com/ABSI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of Absci Corporation
Most recent Consolidated Net Income/Lossof ABSI including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of Absci Corporation
Absci Corporation Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $-21.99 | $-41.67 | $-23.36 | – | – |
| 2022 | $-19.47 | $-27.26 | $-28.68 | $-29.49 | $-104.9 |
| 2021 | $-25.17 | $-23.63 | $-41.2 | $-10.96 | $-100.96 |
| 2020 | $-4.94 | $-3.75 | $-3.01 | $-2.66 | $-14.35 |
| 2019 | – | – | – | – | $-6.58 |
Business Profile of Absci Corporation
Sector: Healthcare
Industry: Biotechnology